Black checkmark with a sparkle and a curved line underneath on a white background.
Company

MeiraGTx Holdings plc

Ticker
MGTX
Sector
Industry
Report date
November 15, 2026
Valye AI Score

100

Very high visibility
Recent developments
Recent developments summary

Recent quarterly results show MeiraGTx reported a Q3 2026 loss with revenue below expectations, while Q2 2026 earnings and revenues surpassed expectations. The company continues to advance its clinical programs and manufacturing capabilities, supported by strategic collaborations and capital raises.

Recent developments:
  • MeiraGTx reported third quarter 2026 financial and operational results including a net loss and revenue of $4.81 million for the quarter ended September 30, 2026 [N1][S2].
  • The company reported a Q3 2026 loss and revenue below expectations [N2].
  • Q2 2026 earnings and revenues surpassed expectations, indicating operational progress [N5].
  • MeiraGTx entered a $400 million investment deal with Oberland Capital in mid-2026 to support its development programs [N1].
  • The company raised $60.8 million gross proceeds through an 'at-the-market' equity offering during the nine months ended September 30, 2026 [S2].
Overview

MeiraGTx Holdings plc is a vertically integrated, clinical-stage genetic medicines company focused on developing gene therapies for inherited and common diseases with unmet medical needs. The company operates two GMP-compliant viral vector manufacturing facilities in London and Shannon, supporting clinical and commercial supply. It has developed proprietary manufacturing platforms and a novel riboswitch gene regulation technology enabling precise control of gene expression via oral small molecules. Strategic collaborations with Johnson & Johnson and Eli Lilly support research, development, and commercialization efforts. The company also acquired assets from Smart Immune to expand into cell therapy. Financially, MeiraGTx reported $4.81 million in revenue and a net loss of $51.21 million for Q3 2026, with strong liquidity ratios and recent capital raises through equity offerings [S1][S2].

Executive summary

MeiraGTx Holdings plc is a clinical-stage genetic medicines company with proprietary manufacturing facilities in the UK and Ireland, a broad pipeline including late-stage clinical programs, and strategic collaborations with Johnson & Johnson and Eli Lilly. As of September 30, 2026, the company reported cash and equivalents of $184.65 million, revenue of $4.81 million, and a net loss of $51.21 million. Liquidity ratios indicate strong short-term financial health. Recent quarterly results show mixed operational performance with a Q3 loss and revenue below expectations, contrasted by Q2 earnings surpassing estimates. The company has raised capital through equity offerings and continues to advance its pipeline and manufacturing capabilities [S1][S2][N1][N2][N5]. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for MGTX

Bull case model:

The company's proprietary riboswitch platform offers a novel approach to gene regulation, potentially enabling precise, dose-responsive control of therapeutic gene expression via oral small molecules. This technology could open new therapeutic avenues in metabolic diseases and biologics delivery. MeiraGTx's strategic collaborations with Johnson & Johnson and Eli Lilly provide financial support and validation of its technology and pipeline. The acquisition of Smart Immune assets expands its cell therapy capabilities, potentially broadening its therapeutic reach. Strong manufacturing infrastructure supports clinical and commercial supply, positioning the company to advance multiple late-stage clinical programs [S1][N1].

Bear case model:

MeiraGTx operates in a highly competitive and regulated biopharmaceutical sector with significant clinical and commercial risks. The company reported a net loss of $51.21 million in Q3 2026 and revenue remains limited, reflecting early-stage commercialization. Stock price volatility and dilution risks exist due to ongoing equity offerings. The success of collaborations depends on milestone achievements and regulatory approvals, which carry uncertainty. Integration of acquired assets and execution of complex manufacturing and development programs pose operational challenges. Market and economic factors, including currency fluctuations and regulatory changes, may adversely impact financial results and shareholder value [S2].

Moat:

MeiraGTx's moat derives from its vertically integrated manufacturing capabilities with two GMP-compliant facilities, proprietary viral vector and plasmid production platforms, and a unique riboswitch gene regulation technology. These assets enable efficient development and scalable production of gene therapies. Strategic collaborations with major pharmaceutical companies like Johnson & Johnson and Eli Lilly provide access to resources, expertise, and potential milestone and royalty revenues. The company's in-house quality control and manufacturing infrastructure support regulatory compliance and commercial readiness, creating barriers to entry for competitors lacking similar integrated capabilities [S1].

Risks overview
Risks summary
The primary risks for MeiraGTx include clinical and regulatory uncertainties inherent in gene therapy development, financial losses requiring capital raises, and operational challenges in manufacturing scale-up and integration of acquisitions.
Risks details:

• Clinical and Regulatory Risk: The development of gene therapies involves significant clinical and regulatory uncertainties that may delay or prevent product approvals.
• Financial Risk: The company has reported net losses and may require additional capital, which could dilute existing shareholders.
• Operational Risk: Integration of acquired assets and scaling manufacturing capabilities may present challenges affecting timelines and costs.
• Market and Shareholder Risk: Stock price volatility and concentration of ownership may impact shareholder interests and market perception.
• Collaborative Risk: Dependence on strategic partners for development, commercialization, and milestone payments introduces execution and financial risks.

FINAL FORECAST FOR MGTX

Final take one line
MeiraGTx Holdings plc is a clinical-stage genetic medicines company with strong manufacturing capabilities, strategic collaborations, and ongoing clinical development, supported by solid liquidity but facing typical clinical-stage risks.
Final take 12 to 24 month view

Business trends: Advancement of late-stage clinical programs, expansion of manufacturing capacity, and strategic collaborations with major pharmaceutical partners.
Execution milestones: Progress in clinical trials, regulatory approvals, and successful integration of acquired assets and capital deployment.
Key risks: Clinical and regulatory uncertainties, financial losses requiring capital raises, operational challenges in manufacturing scale-up, and market volatility.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

100
LLM visibility overview
LLM Visibility known facts
  • MeiraGTx Holdings plc is a vertically integrated, clinical-stage genetic medicines company with a broad pipeline including late-stage clinical programs targeting radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy [S1].
  • The company operates two GMP-compliant viral vector manufacturing facilities: a 29,000 sq ft site in London, UK, and a 150,000 sq ft commercial-scale site in Shannon, Ireland, both designed for clinical and commercial supply [S1].
  • MeiraGTx has proprietary manufacturing platforms with high yield and quality, including internal plasmid production and quality control hubs [S1].
  • The company has developed a proprietary riboswitch gene regulation platform enabling precise, dose-responsive expression of transgenes controlled by oral small molecules, targeting biologic therapeutics and cell therapies [S1].
  • MeiraGTx has strategic collaborations with Johnson & Johnson Innovative Medicine (formerly Janssen) and Eli Lilly for gene therapy development and commercialization, including milestone and royalty arrangements [S1].
  • In December 2023, MeiraGTx sold certain RPGR-related assets to Johnson & Johnson for $65 million upfront plus contingent payments up to $350 million, and continues to manufacture the RPGR product under a supply agreement [S1].
  • In 2025, MeiraGTx entered a strategic collaboration with Hologen Limited involving upfront and potential additional funding totaling up to $430 million, with shared governance and licensing arrangements for CNS-targeted gene therapies and delivery devices [S1].
  • The company acquired assets of Smart Immune in 2025 to advance off-the-shelf allogenic ProTcell-derived CAR-T therapies incorporating riboswitch technology [S1].
  • Financial snapshot as of September 30, 2026 (Q3 2026): cash and equivalents of $184.65 million, current assets of $242.35 million, current liabilities of $52.40 million, revenue of $4.81 million, net loss of $51.21 million, basic and diluted EPS of -$0.53 [S2].
  • Liquidity ratios as of September 30, 2026: current ratio 4.62, cash ratio 3.52, indicating strong short-term liquidity [S2].
  • During the nine months ended September 30, 2026, MeiraGTx raised $60.8 million gross proceeds through an 'at-the-market' equity offering program [S2].
  • Recent quarterly results show Q3 2026 loss and revenue below expectations, while Q2 2026 earnings and revenues surpassed expectations [N1][N2][N5].
  • The company has ongoing collaborations and licensing agreements with major pharmaceutical companies, supporting its clinical development and manufacturing capabilities [S1][N1].
  • MeiraGTx's executive officers, directors, and principal shareholders collectively hold approximately 43.36% of outstanding shares, enabling significant influence over corporate matters [S2].
  • The company faces risks typical of clinical-stage biopharmaceutical firms, including stock price volatility, potential dilution from equity offerings, and regulatory and operational risks [S2].
Sources
Sources - Context summary

Generated 2026-11-15

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-30 | 10-K
  • S2 | 2026-11-12 | 10-Q
Sources - News headlines
  • N1 | 2026-11-13 | www.nasdaq.com | MeiraGTx Holdings plc Reports Third Quarter 2026 Financial and Operational Results | https://www.nasdaq.com/articles/meiragtx-holdings-plc-reports-third-quarter-2026-financial-and-operational-results
  • N2 | 2026-11-12 | www.nasdaq.com | MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Misses Revenue Estimates | https://www.nasdaq.com/articles/meiragtx-holdings-plc-mgtx-reports-q3-loss-misses-revenue-estimates
  • N3 | 2026-11-11 | www.nasdaq.com | Alpha Cognition Inc. (ACOG) Reports Q3 Loss, Beats Revenue Estimates | https://www.nasdaq.com/articles/alpha-cognition-inc-acog-reports-q3-loss-beats-revenue-estimates
  • N4 | 2026-11-10 | www.nasdaq.com | Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Misses Revenue Estimates | https://www.nasdaq.com/articles/orchestra-biomed-holdings-inc-obio-reports-q3-loss-misses-revenue-estimates
  • N5 | 2026-08-13 | www.nasdaq.com | MeiraGTx Holdings PLC (MGTX) Q2 Earnings and Revenues Surpass Estimates | https://www.nasdaq.com/articles/meiragtx-holdings-plc-mgtx-q2-earnings-and-revenues-surpass-estimates
  • N6 | 2026-08-12 | www.nasdaq.com | TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates | https://www.nasdaq.com/articles/tscan-therapeutics-inc-tcrx-reports-q2-loss-misses-revenue-estimates
  • N7 | 2026-08-06 | www.nasdaq.com | Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates | https://www.nasdaq.com/articles/voyager-therapeutics-vygr-reports-q2-loss-misses-revenue-estimates
  • N8 | 2026-08-04 | www.nasdaq.com | Pacira (PCRX) Tops Q2 Earnings and Revenue Estimates | https://www.nasdaq.com/articles/pacira-pcrx-tops-q2-earnings-and-revenue-estimates
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine